IgE and non-IgE-mediated food allergy: treatment in 2007
- 1 June 2007
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Allergy and Clinical Immunology
- Vol. 7 (3), 264-268
- https://doi.org/10.1097/aci.0b013e32814a5607
Abstract
Our understanding of the mechanism of food allergy has substantially increased over the past decade. Food allergies can be classified into those that are IgE mediated and those that are non-IgE mediated. Various advances have been made in treating IgE-mediated food allergies. A phase II clinical trial of a second anti-IgE antibody, omalizumab, was recently initiated in subjects with peanut allergy, but was stopped as a result of safety concerns after severe reactions occurred during initial oral challenges. Oral immunotherapy is showing promise in various studies on patients with IgE-mediated food allergies. Gastrointestinal food allergic disorders involving non-IgE-mediated food allergies have recently received attention, particularly eosinophilic esophagitis. Although amino acid-based formula therapy remains the most successful in controlling inflammation and symptoms in these disorders, other therapeutic options including various dietary elimination protocols and swallowed fluticasone are showing success. Anti-IL-5 therapy may prove to be a promising future therapeutic option for refractory patients. Although there are no specific therapeutic recommendations for many IgE-mediated and non-IgE-mediated food allergic disorders besides allergen avoidance, various novel approaches are currently being investigated and may influence treatment approaches in the future.Keywords
This publication has 42 references indexed in Scilit:
- A Phase II, Randomized, Double-Blind, Parallel-group, Placebo-Controlled, Oral Food Challenge Trial of XOLAIR® (omalizumab) in Peanut Allergy (TOPS)Journal of Allergy and Clinical Immunology, 2007
- Food allergen labeling in the USA and EuropeCurrent Opinion in Allergy and Clinical Immunology, 2006
- 9. Food allergyJournal of Allergy and Clinical Immunology, 2006
- Omalizumab is Effective and Safe in the Treatment of Japanese Cedar Pollen-induced Seasonal Allergic RhinitisAllergology International, 2006
- Omalizumab : Other Indications and Unanswered QuestionsClinical Reviews in Allergy & Immunology, 2005
- Prevalence of seafood allergy in the United States determined by a random telephone surveyJournal of Allergy and Clinical Immunology, 2004
- Update on food allergyJournal of Allergy and Clinical Immunology, 2004
- Effect of Anti-IgE Therapy in Patients with Peanut AllergyThe New England Journal of Medicine, 2003
- Treatment of anaphylactic sensitivity to peanuts by immunotherapy with injections of aqueous peanut extract1Journal of Allergy and Clinical Immunology, 1997
- Treatment of peanut allergy with rush immunotherapyJournal of Allergy and Clinical Immunology, 1992